Nuvalent Other Current Liab from 2010 to 2024

NUVL Stock  USD 95.62  0.69  0.73%   
Nuvalent Other Current Liabilities yearly trend continues to be quite stable with very little volatility. Other Current Liabilities may rise above about 23.7 M this year. From the period between 2010 and 2024, Nuvalent, Other Current Liabilities regression line of its data series had standard deviation of  6,957,230 and standard deviation of  6,957,230. View All Fundamentals
 
Other Current Liabilities  
First Reported
2010-12-31
Previous Quarter
22.5 M
Current Value
23.7 M
Quarterly Volatility
M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Nuvalent financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Nuvalent's main balance sheet or income statement drivers, such as Depreciation And Amortization of 159.5 K, Interest Expense of 24.4 M or Selling General Administrative of 38.1 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 6.42. Nuvalent financial statements analysis is a perfect complement when working with Nuvalent Valuation or Volatility modules.
  
Check out the analysis of Nuvalent Correlation against competitors.
For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.

Latest Nuvalent's Other Current Liab Growth Pattern

Below is the plot of the Other Current Liab of Nuvalent over the last few years. It is Nuvalent's Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Nuvalent's overall financial position and show how it may be relating to other accounts over time.
Other Current Liab10 Years Trend
Slightly volatile
   Other Current Liab   
       Timeline  

Nuvalent Other Current Liab Regression Statistics

Arithmetic Mean6,920,897
Geometric Mean5,151,657
Coefficient Of Variation100.52
Mean Deviation5,033,168
Median3,628,000
Standard Deviation6,957,230
Sample Variance48.4T
Range20.5M
R-Value0.70
Mean Square Error26.6T
R-Squared0.49
Significance0
Slope1,088,283
Total Sum of Squares677.6T

Nuvalent Other Current Liab History

202423.7 M
202322.5 M
202212.3 M
20215.9 M
20203.1 M

About Nuvalent Financial Statements

Nuvalent investors utilize fundamental indicators, such as Other Current Liab, to predict how Nuvalent Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Other Current Liabilities22.5 M23.7 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Nuvalent is a strong investment it is important to analyze Nuvalent's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Nuvalent's future performance. For an informed investment choice regarding Nuvalent Stock, refer to the following important reports:
Check out the analysis of Nuvalent Correlation against competitors.
For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.
You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.49)
Return On Assets
(0.19)
Return On Equity
(0.30)
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.